Frazier Life Sciences

Frazier Life Sciences is a private equity and venture capital firm established in 1991 and based in Seattle, Washington, with a focus on investing in and building companies that develop and commercialize novel therapeutics. The firm targets a wide range of investment stages, from company formation to public offerings, and emphasizes opportunities addressing unmet medical needs within the healthcare sector. Frazier Life Sciences invests primarily in drug development, including pre-clinical and clinical opportunities, and has a preference for profitable companies in healthcare services, pharmaceutical services, medical products, and biotechnology. The firm typically commits between $3 million and $100 million per transaction, often taking a majority stake and acting as a lead investor to actively support portfolio companies through its extensive network of healthcare executives and industry experts. Frazier Life Sciences seeks to invest in companies located in North America and Europe, particularly in innovation hubs such as the Bay Area, San Diego, Seattle, Boston, and North Carolina.